EGFR and non-small cell lung carcinoma: For example, epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) targeted therapy can remarkably improve the prognosis of patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) and is considered as standard first-line treatment for these patients (2).